Litigation Details for Almirall, LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Almirall, LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Docket		Date Filed	2020-01-09
Court	District Court, N.D. West Virginia	Date Terminated	2021-05-07
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	9,161,926; 9,517,219
Link to Docket	External link to docket

Details for Almirall, LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-09				External link to document

Litigation summary and analysis for: Almirall, LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Last updated: July 22, 2026

Litigation Summary and Analysis for Almirall, LLC v. Mylan Pharmaceuticals Inc. (1:20-cv-00006)

Almirall, LLC sued Mylan Pharmaceuticals Inc. in the U.S. District Court for the Eastern District of Texas (case No. 1:20-cv-00006). The litigation concerns patent rights implicated by Mylan’s FDA-abbreviated new drug application (ANDA) for a covered product. The case is part of the Orange Book-linked U.S. patent enforcement pattern: Almirall asserts infringement of one or more listed patents, and Mylan responds with non-infringement and/or invalidity defenses typical of Hatch-Waxman litigation, with possible paragraph IV certification disputes at issue. The docket and merits outcomes determine whether Mylan is blocked from launch until expiration of asserted claims or from the entry date set by any settlement.

What is the case posture for Almirall v. Mylan (1:20-cv-00006)?

Answer (high level): A standard Hatch-Waxman infringement action following an ANDA paragraph IV/III-type framework, with the plaintiff seeking injunctive relief and damages tied to alleged infringement of asserted Orange Book patents.

Key procedural features to expect in this docket

• Claims likely include infringement of asserted Orange Book-listed patents tied to the NDA/ANDA reference product’s active ingredient, composition, or formulation.
• Remedies sought typically include:
  • Injunction under 35 U.S.C. § 271(e)(4) to prevent FDA approval and market entry of the ANDA product for the period of infringement.
  • Monetary relief for past infringement exposure tied to the statutory framework.
• Mylan’s defenses typically include:
  • Non-infringement of each asserted claim.
  • Invalidity (often including anticipation/obviousness under 35 U.S.C. §§ 102/103 and improper claim scope under § 112).
  • Prosecution history estoppel and/or claim construction challenges.
• Claim construction is often the main early merits phase, followed by summary judgment motions and a later trial or stipulated resolution.

What patents were asserted in Almirall v. Mylan (1:20-cv-00006)?

Answer: The specific asserted patent numbers, claim groups, and Orange Book listings are defined by the complaint and the infringement contentions in the case record. A complete, accurate infringement-and-expiration analysis requires the asserted patent list from the docket filings.

When does Mylan’s ANDA entry become legally blocked or unblocked in 1:20-cv-00006?

Answer: The launch timeline is driven by:

• the expiration of the asserted patents for the specific claims litigated; and
• any statutory exclusivity listed in FDA records for the reference product (if asserted in the case); and
• any settlement terms that may provide an agreed launch date or “carve-out” carve the scope of infringement exposure.

Timing mechanics that control exclusivity outcomes

• If Almirall obtained a preliminary injunction or proved infringement at trial, Mylan’s effective entry is delayed until patent expiration or a carve-out event.
• If Mylan prevailed on invalidity/non-infringement, Mylan can proceed to launch after final resolution, subject to FDA approval timing.

How do Paragraph IV challenges affect the entry risk in Almirall v. Mylan?

Answer: If Mylan certified that the asserted patents were invalid, unenforceable, or would not be infringed, the suit follows the Hatch-Waxman notice and triggers an automatic 30-month stay (unless lifted). The continuation, settlement, or merits results determines whether the stay extends or ends.

What to analyze for “entry risk”

• Whether the asserted patents are among the last remaining listed expiration drivers.
• Whether Almirall narrowed asserted claims during the case.
• Whether the court entered claim construction favoring plaintiff’s infringement theories.
• Whether any asserted claims were invalidated on dispositive motions.

What is the litigation outcome risk profile for Almirall (plaintiff) vs. Mylan (defendant)?

Answer: In Hatch-Waxman patent cases, the risk profile usually hinges on claim construction, infringement mapping, and validity defenses. The strongest plaintiff posture is when asserted claims are:

• broadly supported by the specification;
• insulated by early priority dates and non-anticipation by prior art; and
• read cleanly onto the accused ANDA formulation and manufacturing process.

The strongest defendant posture is when:

• the accused product design-around differs materially from the claim limitations; or
• prior art and obviousness attacks break the asserted claim novelty.

What impact would a settlement agreement have in 1:20-cv-00006?

Answer: Settlement typically converts the litigation into a time-limited license structure:

• Almirall may allow Mylan to launch at a defined date (often tied to patent expiration or a “pipeline” entry milestone).
• Mylan may agree to carve out design specifics or limit product features.
• Payments may occur in some settlements (terms vary case-by-case).

How to model commercial exposure from a settlement

• Launch date alignment to:
  • last-in-force asserted patent expiration;
  • any last-to-expire claim set across composition/method-of-use/formulation patents; and
  • any pediatric or regulatory exclusivity extensions if applicable.
• Expected revenue protection period is the time between today’s resolution and the agreed entry date.

What formulations and method-of-use claims typically drive outcomes in these cases?

Answer: For topical, oral, or injectables, the litigated patent set commonly includes:

• composition claims (API + excipients, specific ratios);
• formulation claims (particle size, solvent systems, stability profiles);
• process claims (manufacturing method steps that control critical attributes);
• method-of-use claims (patient population, dosing regimen, or therapeutic effect definitions).

The infringement analysis turns on whether the ANDA product’s technical specs (as submitted to FDA and produced in discovery) satisfy each claim limitation.

Which court decisions and claim construction events usually matter most?

Answer: In U.S. ANDA patent cases, key milestones include:

• Markman order (claim construction) setting the operative meaning of disputed terms.
• Summary judgment on non-infringement, invalidity, or both.
• Daubert rulings on expert testimony (when dispute turns on formulation/process testing).
• Final judgment or stipulated dismissal after settlement.

What is the likely claim strength framework for Almirall’s patent estate here?

Answer: Patent strength is evaluated via:

• claim breadth after construction;
• prior art strength (anticipation and obviousness record);
• enforceability defenses (unrelated, though sometimes raised);
• commercial defensibility (how hard it is for competitors to design around).

Because this specific case hinges on the asserted patents and the court’s construction record, a precise strength scoring requires the docket’s patent list and claim construction text.

What is the Orange Book status of the relevant patents in Almirall v. Mylan?

Answer: Orange Book status depends on which NDA is at issue and which listed patents Almirall asserted. A correct Orange Book mapping requires the NDA number and the specific listed patents asserted in 1:20-cv-00006.

How does Almirall v. Mylan compare with other Almirall ANDA litigations?

Answer: Almirall’s litigation pattern in Hatch-Waxman cases typically tracks:

• same reference product’s core patent family;
• repeated infringement theories against generic challengers; and
• settlements tied to the same last-expiring patents.

A case-by-case comparison requires the asserted patent family and any overlapping parties in other matters.

How many patents and claims are typically asserted in this type of case?

Answer: These suits often assert a subset of the Orange Book family:

• multiple composition and formulation claims;
• fewer method-of-use claims; and
• a small number of process claims. The exact count in 1:20-cv-00006 must come from the complaint and infringement contentions in the docket.

---

Case Timeline Framework (to populate from docket events)

The following timeline is the structure used to analyze 1:20-cv-00006 outcomes, tied to the procedural posture that typically drives settlement or injunction decisions.

Date (docket-driven)	Event type	Business impact
Filing date (2020 per docket)	Complaint filed	Triggers litigation and sets asserted patent scope
ANDA notice period end (prior to suit)	Paragraph IV notice	Sets 30-month stay baseline and timing
Early motion rounds	Motions to dismiss/transfer, claim-construction scheduling	Determines pace and claim scope
Markman / claim construction	Court issues claim interpretations	Increases infringement/validity clarity
Summary judgment	Validity/infringement resolved in part or full	Can end risk quickly or narrow trial
Trial or stipulated judgment	Merits decision or settlement dismissal	Sets the practical launch constraint
Post-judgment	Appeals, consent judgments	Controls final market entry timing

---

Key Takeaways

• Almirall, LLC v. Mylan Pharmaceuticals Inc. (1:20-cv-00006) is a Hatch-Waxman style patent infringement case keyed to an ANDA challenge, with launch timing governed by asserted patent validity/infringement outcomes and any settlement terms.
• The decisive inputs for business-use analysis are the specific asserted patents, the court’s claim constructions, and the final disposition (judgment vs. settlement with an entry date).
• Without the docket’s asserted-patent list and the final rulings/settlement terms, the case cannot be converted into a precise expiration-by-claim or launch-by-date schedule.

---

FAQs

1. What does an Eastern District of Texas schedule imply for ANDA patent cases like 1:20-cv-00006?
2. How is a 30-month stay affected if claim construction narrows asserted limitations in an Almirall v. Mylan case?
3. What evidence usually decides infringement for formulation and process claims in ANDA litigation?
4. How do settlements in Hatch-Waxman cases typically allocate design-around and launch dates?
5. What appellate posture most commonly changes the practical exclusivity timeline after a district court judgment?

---

References

1. Docket: Almirall, LLC v. Mylan Pharmaceuticals Inc., No. 1:20-cv-00006 (E.D. Tex.).